Literature DB >> 2807618

Pharmacokinetics of a nitrofuran compound, nifurtimox, in healthy volunteers.

C Paulos1, J Paredes, I Vasquez, S Thambo, A Arancibia, G Gonzalez-Martin.   

Abstract

Nifurtimox disposition was evaluated in 7 healthy volunteers. Each subject received an oral dose of 15 mg/kg of nifurtimox and blood sample was obtained 11 h after the drug administration. We used an analytical method previously assessed in the literature. The pharmacokinetic analysis was carried out according to a one-compartment model and the most important parameters established were elimination half-life, distribution volume, and clearance. Serum concentrations were low in relation to the high doses administered. The low serum concentration is probably the result of a marked first pass effect.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2807618

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  10 in total

1.  Computational models to assign biopharmaceutics drug disposition classification from molecular structure.

Authors:  Akash Khandelwal; Praveen M Bahadduri; Cheng Chang; James E Polli; Peter W Swaan; Sean Ekins
Journal:  Pharm Res       Date:  2007-09-11       Impact factor: 4.200

2.  Nifurtimox Is Ineffective against Drug-Resistant Mycobacteria.

Authors:  Mike Marvin Ruth; Jasper Jan Nicolaas Sangen; Heiman Frank Louis Wertheim; Jakko van Ingen
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

3.  Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.

Authors:  Antoaneta Y Sokolova; Susan Wyllie; Stephen Patterson; Sandra L Oza; Kevin D Read; Alan H Fairlamb
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

4.  The pharmacokinetics of nifurtimox in chronic renal failure.

Authors:  G González-Martin; S Thambo; C Paulos; I Vásquez; J Paredes
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 5.  Pediatric clinical pharmacology studies in Chagas disease: focus on Argentina.

Authors:  Facundo Garcia-Bournissen; Jaime Altcheh; Norberto Giglio; Guido Mastrantonio; Carlos Omar Della Védova; Gideon Koren
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 6.  Human African trypanosomiasis: pharmacological re-engagement with a neglected disease.

Authors:  M P Barrett; D W Boykin; R Brun; R R Tidwell
Journal:  Br J Pharmacol       Date:  2007-07-09       Impact factor: 8.739

7.  ALDH2 mediates 5-nitrofuran activity in multiple species.

Authors:  Linna Zhou; Hironori Ishizaki; Michaela Spitzer; Kerrie L Taylor; Nicholas D Temperley; Stephen L Johnson; Paul Brear; Philippe Gautier; Zhiqiang Zeng; Amy Mitchell; Vikram Narayan; Ewan M McNeil; David W Melton; Terry K Smith; Mike Tyers; Nicholas J Westwood; E Elizabeth Patton
Journal:  Chem Biol       Date:  2012-07-27

8.  Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine.

Authors:  Michael Du; Linna Zhang; Kathleen A Scorsone; Sarah E Woodfield; Peter E Zage
Journal:  Sci Rep       Date:  2016-06-10       Impact factor: 4.379

9.  Dipyridamole potentiated the trypanocidal effect of nifurtimox and improved the cardiac function in NMRI mice with acute chagasic myocarditis.

Authors:  Sonia Santeliz; Peter Caicedo; Elidiosmar Giraldo; Carmen Alvarez; María-Daniela Yustiz; Claudina Rodríguez-Bonfante; Romina Bonfante-Rodríguez; Rafael Bonfante-Cabarcas
Journal:  Mem Inst Oswaldo Cruz       Date:  2017-09       Impact factor: 2.743

10.  Biopharmaceutical Characteristics of Nifurtimox Tablets for Age- and Body Weight-Adjusted Dosing in Patients With Chagas Disease.

Authors:  Heino Stass; Ethel Feleder; Facundo Garcia-Bournissen; Johannes Nagelschmitz; Boris Weimann; Gustavo Yerino; Jaime Altcheh
Journal:  Clin Pharmacol Drug Dev       Date:  2020-10-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.